Veradigm® · 1 day ago
AVP Life Sciences Sales, Real-World Evidence - East Coast Remote
Veradigm is dedicated to transforming healthcare through innovative data-driven solutions. The AVP of Life Sciences Sales will lead the go-to-market strategy for Veradigm's life sciences solutions, focusing on real-world evidence and data, while cultivating relationships with key stakeholders in the pharmaceutical and biotech industries.
Electronic Health Record (EHR)Health CareHospitalInformation ServicesInformation Technology
Responsibilities
Develop and execute a robust sales plan targeting life sciences organizations RWE solutions
Find and develop opportunities to sell RWD to those life sciences organizations through RWE engagements
Build, mentor, and oversee a high-performing sales team including SDRs, AEs, and strategic account leaders
Drive new business and expand key client relationships within pharma, biotech, CROs, and related stakeholders
Lead executive-level engagements to align Veradigm’s RWE capabilities with client strategic objectives
Collaborate with product, clinical, and marketing teams to position Veradigm’s offerings—such as VNEHR data augmented by NLP, social determinants of health (SDoH), and mortality data—as strategic tools for regulatory, HEOR, and market access use cases
Educate prospects on RWE and RWD’s value in supporting clinical trial optimization, safety surveillance, outcomes research, patient journey mapping, and regulatory submissions
Collaborate with marketing and product leadership to craft positioning, messaging, and collateral around RWE capabilities
Articulate the strategic advantages of Veradigm’s data assets—150M+ patient records across 80+ EHR systems with structured & unstructured data using advanced NLP—to influence C-suite stakeholders
Partner with Product, R&D, Clinical Services, and Legal/Compliance teams to refine offerings and ensure alignment with client needs and industry regulations
Coordinate with client services to support proofs-of-concept, pilots, and post-sales adoption, ensuring strong delivery and client satisfaction
Track industry trends, competitor solutions, and healthcare data regulations to continuously refine go-to-market strategies and product positioning
Qualification
Required
10+ years in life sciences or healthcare analytics sales, including proven experience selling real-world or clinical data solutions (RWD/RWE) to Pharma, Biotech, CROs, or HEOR teams
Demonstrated success in building and managing enterprise-level sales teams with leadership experience
Strong understanding of RWD sources—EHR data, unstructured clinical notes, SDoH, mortality—and their applications in clinical research, regulatory strategy, and market analytics
Proven track record closing complex deals involving data licensing, analytic services, or SaaS platforms within regulated environments
Exceptional presentation skills and executive-level influence
Strategic thinker with analytical rigor and ability to connect RWD capabilities to client business outcomes
Willingness to travel (~40–50%) to meet with clients and at industry conferences
Preferred
Advanced degree (MBA, MPH, or MS) in life sciences, public health, or business
Experience selling AI-driven or NLP-enhanced healthcare data solutions, especially those using unstructured EHR insights
Familiarity with AWS, Datavant Connect, or similar platforms facilitating RWD marketplace and cloud-based access
Existing relationships and credibility with pharma, biotech, or CRO leadership
Benefits
Holidays
Vacation
Medical
Dental
Vision insurance
Company paid life insurance
Retirement savings
Company
Veradigm®
Veradigm is an integrated data systems and services company that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery—these stakeholders include biopharma, health plans, healthcare providers, network partners, and most importantly, the patients they serve.
Funding
Current Stage
Public CompanyTotal Funding
$175MKey Investors
NantCapital
2025-06-18Post Ipo Debt· $75M
2015-06-30Post Ipo Equity· $100M
2008-03-18Acquired
Recent News
2025-12-16
2025-11-11
Company data provided by crunchbase